Tvardi Therapeutics (NASDAQ:TVRD) Downgraded to Sell Rating by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Lucid Cap Mkts raised Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.50.

Tvardi Therapeutics Price Performance

Shares of NASDAQ TVRD opened at $3.99 on Friday. The firm’s 50-day moving average is $4.08 and its two-hundred day moving average is $13.10. The company has a market capitalization of $37.43 million, a PE ratio of -0.41 and a beta of 0.14. Tvardi Therapeutics has a 12-month low of $3.50 and a 12-month high of $43.65.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new stake in Tvardi Therapeutics in the 2nd quarter worth about $2,617,000. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $39,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $92,000. Marshall Wace LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $583,000. Finally, Slate Path Capital LP acquired a new stake in shares of Tvardi Therapeutics in the second quarter worth approximately $16,427,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.